EGFR and neoplasm: Analysis in strata according to adjuvant treatment, however, revealed a significantly reduced RFS and OS for patients that had received adjuvant gemcitabine and had tumours with high, as compared with low, EGFR expression (Fig 3A and 3B), whereas no survival difference was seen according to high or low EGFR expression among untreated PB-type cases (Fig 3).